Ainos Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ainos.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	27.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Sep 30

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Aug 24

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Aug 15

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ainos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:AIMD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	0	-15	-6	-6	N/A
3/31/2024	0	-15	-5	-5	N/A
12/31/2023	0	-14	-5	-5	N/A
9/30/2023	1	-10	-4	-4	N/A
6/30/2023	3	-15	-4	-4	N/A
3/31/2023	3	-14	-4	-3	N/A
12/31/2022	4	-14	-4	-3	N/A
9/30/2022	3	-13	-4	-3	N/A
6/30/2022	1	-7	-3	-3	N/A
3/31/2022	1	-5	-3	-2	N/A
12/31/2021	1	-4	-1	-1	N/A
9/30/2021	1	-3	-1	-1	N/A
6/30/2021	0	-2	0	0	N/A
3/31/2021	0	-2	-1	-1	N/A
12/31/2020	0	-1	-1	0	N/A
9/30/2020	0	-1	-1	-1	N/A
6/30/2020	0	-1	-1	-1	N/A
3/31/2020	0	-2	-1	-1	N/A
12/31/2019	0	-2	-1	-1	N/A
9/30/2019	0	-2	-1	-1	N/A
6/30/2019	0	-2	-1	-1	N/A
3/31/2019	0	-2	-1	-1	N/A
12/31/2018	0	-1	-1	-1	N/A
9/30/2018	0	-1	-1	-1	N/A
6/30/2018	0	-1	-1	-1	N/A
3/31/2018	0	-1	N/A	0	N/A
12/31/2017	0	-1	N/A	0	N/A
9/30/2017	0	-1	N/A	0	N/A
6/30/2017	0	-1	N/A	0	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
9/30/2016	0	-1	N/A	-1	N/A
6/30/2016	0	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	0	N/A
12/31/2015	N/A	-1	N/A	0	N/A
9/30/2015	N/A	3	N/A	0	N/A
6/30/2015	N/A	3	N/A	-1	N/A
3/31/2015	N/A	3	N/A	-1	N/A
12/31/2014	N/A	3	N/A	-1	N/A
9/30/2014	N/A	-1	N/A	0	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AIMD's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if AIMD's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AIMD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AIMD's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AIMD's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AIMD's Return on Equity is forecast to be high in 3 years time

Ainos Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona

Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients

Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Second quarter 2024 earnings released: US$0.49 loss per share (vs US$0.58 loss in 2Q 2023)

Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023)

New major risk - Shareholder dilution

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022)

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

New minor risk - Shareholder dilution

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021)

Ainos Receives Non-Compliance Notice From Nasdaq

Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021)

Less than half of directors are independent

Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and Commercialization

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - Omicron

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021)

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million.

Less than half of directors are independent

Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19

Ainos, Inc. Announces Executive Changes

Ainos, Inc. announced delayed 10-Q filing

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies